All News
Filter News
Found 54 articles
-
Pfizer Completes Acquisition of Biohaven Pharmaceuticals
10/3/2022
Pfizer Inc. announced the completion of its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC® ODT, an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults.
-
Biohaven Announces Record Date for Anticipated Spin-Off
9/19/2022
Biohaven Pharmaceutical Holding Company Ltd. announced that it has set a record date of September 26, 2022 for the previously announced spin-off by Biohaven of its Biohaven Ltd. subsidiary, which will own the Kv7 ion channel activators, glutamate modulation, myeloperoxidase inhibition and myostatin inhibition platforms, preclinical product candidates, and certain corporate infrastructure currently owned by Biohaven.
-
Freedom Biosciences Emerges from Stealth with $10.5 Million Seed Financing to Develop Next-Generation Ketamine and Psychedelic-based Mental Health Treatments
8/23/2022
Freedom Biosciences today emerged from stealth with $10.5 million in seed financing.
-
Biohaven Reports Second Quarter 2022 Financial Results and Reports Recent Business Developments
8/5/2022
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, today reported financial results for the second quarter ended June 30, 2022, and provided a review of recent accomplishments during and anticipated upcoming milestones.
-
Pfizer Reports Second-Quarter 2022 Results
7/28/2022
Pfizer Inc. reported strong financial results for second-quarter 2022 and updated certain components of 2022 financial guidance.
-
Obsessive Compulsive Disorder Market Will Reflect the Noticeable CAGR by the end of Forecast Period 2030
7/26/2022
Forecast to 2030,’ thoroughly examines the Obsessive Compulsive Disorder industry to provide essential data & information for the targeted readers.
-
Knopp Biosciences and Population Health Partners Create Areteia Therapeutics, New Clinical-Stage Asthma Company, with $350 Million in Funding
7/12/2022
Areteia will initiate Phase 3 trials of lead candidate, dexpramipexole, a potential first-in-class oral drug for eosinophilic asthma, in late 2022.
-
Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma
6/30/2022
Strengthens balance sheet with significant non-dilutive, low-cost capital Expands ability to bring the promise of precision therapy to broad patient populations through internal R&D and strategic business development Propelled by global launches of AYVAKIT®/AYVAKYT® (avapritinib) and GAVRETO®.
-
A new report by PwC projects that the second half of this year will see a “flurry of deals activity across all areas of the sector.”
-
Pfizer made the splash of the young week Tuesday morning, inking an acquisition deal with New Haven, Connecticut-based Biohaven Pharma totaling $11.6 billion.
-
Biohaven Reports First Quarter 2022 Financial Results and Reports Recent Business Developments
5/10/2022
Biohaven Pharmaceutical Holding Company Ltd. reported financial results for the first quarter ended March 31, 2022, and provided a review of recent accomplishments during and anticipated upcoming milestones.
-
Pfizer to Acquire Biohaven Pharmaceuticals
5/10/2022
Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven, the maker of NURTEC® ODT, an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults.
-
Pfizer Reports First-Quarter 2022 Results
5/3/2022
Pfizer Inc. reported strong financial results for first-quarter 2022 and updated certain components of 2022 financial guidance.
-
Biohaven Pharmaceutical Holding announced the acquisition of Channel Bio and new licensing rights to a spinal muscle atrophy drug from Bristol Myers Squibb.
-
BIOHAVEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS
2/25/2022
Biohaven Pharmaceutical Holding Company Ltd. today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a review of accomplishments during 2021 and anticipated upcoming milestones.
-
Pfizer Reports Fourth-Quarter and Full-Year 2021 Results
2/8/2022
Pfizer Inc. (NYSE: PFE) reported strong financial results for fourth-quarter and full-year 2021 and provided 2022 total company financial guidance(4).
-
LAKEWOOD-AMEDEX APPOINTS TWO NEW BOARD MEMBERS
1/25/2022
Elects Thomas Pfisterer and Douglas Manion, MD, FRCP(C), to the Board of Directors.
-
Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic Antibodies against GPCR Targets
12/16/2021
Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in GPCR-focused structure-based drug design (SBDD) and development, and Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced a strategic collaboration to discover therapeutic antibodies against G protein-coupled receptors (GPCR) identified by Sosei Heptares.
-
Biohaven and Pfizer have partnered to market the Nurtec migraine medicine outside the U. S. once approved by global regulatory organizations. Here's more about it.
-
Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States
11/9/2021
Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States